Neuroprotective effect of dexmedetomidine in a murine model of traumatic brain injury

Jin Wu1, Todd Vogel2, Xiang Gao3, Bin Lin1, Charles Kulwin2 & Jinhui Chen2,3

No FDA approved pharmacological therapy is available that would reduce cell death following traumatic brain injury (TBI). Dexmedetomidine (Dex) is a highly selective agonist of alpha-2 adrenergic receptors and has demonstrated neuroprotective effects in hippocampal slice cultures undergoing direct impact. However, no one has tested whether Dex, in addition to its sedative action, has neuroprotective effects in an animal model of TBI. Thus, in the present study, we investigated the effects of Dex on an animal model of TBI. Mice received different doses of Dex (1, 10, or 100 µg/kg bodyweight, n = 10 each group) or saline as control at 1 hour and 12 hours following TBI. The mice treated with Dex lost less cortical tissue than the control mice. Further analysis found that Dex treatment reduced cell death in the cortex and the hippocampus measured by Fluoro-Jade B (FJB) staining, prevented axonal degeneration detected by immunostaining with antibody against β-amyloid precursor protein (β-APP), and protected synapses from elimination with synaptophysin staining. Taken together, in an in vivo murine model of TBI, Dex at the dose of 100 µg/kg not only prevented tissue lesion and cell death, but also reduced axonal injury and synaptic degeneration caused by TBI.

Traumatic brain injury (TBI) takes a devastating annual toll, resulting in 52,000 deaths and 2.0 to 2.5 million emergency room visits annually in the USA. As the leading cause of death and disability in people ages 1 to 44, TBI is especially morbid for an otherwise young and healthy population1–4. Survivors suffer not only physical dysfunction, but also neurobehavioral disabilities, as well as increased susceptibility to the development of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease4,5. Permanent functional deficits in victims limit their productivities at home or during work, thus bringing about a heavy socioeconomic burden to families and communities. Thus, it is critical to develop therapeutic approaches to reduce TBI-induced brain damage.

In addition to the primary traumatic injury, TBI has been shown to involve secondary injury mechanisms including microvascular ischemia, autonomic dysregulation, and neuronal excitotoxicity6–8. Although numerous investigations have explored developing neuroprotective reagents9–14, none of them have been successful in clinical trials to date. Because no FDA approved pharmacological therapy is currently available to reduce cell death following TBI, it is critical to evaluate existing, FDA-approved agents for unrecognized therapeutic benefit in this disease process. Currently, pharmacologic sedation is the first-line treatment for elevated intracranial pressure in severe TBI.

Dexmedetomidine (Dex) is a highly selective alpha-2 adrenergic receptor agonist currently approved for sedation during mechanical ventilation in adults15. Dex has been used in patients with TBI and has shown no risk of affecting brain oxygenation16 or causing hemodynamic physiological changes17. More importantly, Dex interests neurosurgeons and neurologists alike because it has demonstrated neuroprotective effects in animal models of ischemia/reperfusion18 and excitotoxicity19. Additionally, multiple studies have indicated the value of autonomic modulation in animal TBI models, demonstrating the effectiveness of alpha agonists20, beta blockers21, and vagal nerve stimulation22. An in vitro study showed neuroprotection of Dex in hippocampal slice cultures undergoing direct impact23. However, there has been a paucity of investigation into the neuroprotective effects of Dex in animal traumatic models. No one has tested whether Dex, in addition to its sedative action, has neuroprotective effects in an animal model of TBI.
effects in an animal model following TBI. In the present study, we evaluated the effects of Dex in a murine model of TBI to determine if it offers neuroprotective benefits.

Materials and Methods

Animals. Male C57 BL/6 mice were used in experiments at an age of 8 weeks. All procedures were performed under protocols approved by Indiana University’s Animal Care and Use Committee (IACUC). All methods were performed in accordance with the guidelines approved by Indiana University Institutional Biosafety Committee.

Controlled Cortical Impact Traumatic Brain Injury. Eight-week-old mice (n = 76) were subjected to moderate, controlled cortical impact injury (CCI), as we previously described24,25. The mouse CCI model uses an electromagnetic impactor (Impact OneTM, Stereotactic Impactor for CCI, Leica Microsystems, Illinois, USA). For this study, the contact velocity was set at 3.0 m/sec and the deformation was set at 1.0 mm. These settings resulted in an injury of moderate severity. Following injury induction, the skin incision was sutured. Sham (non-injured) mice (n = 18) were subjected to craniotomy, but did not receive a CCI injury.

Dex treatment. After surgery, the CCI-injured mice (n = 60) were randomized for placement into saline or Dex treatment groups. The mice then received intraperitoneal (i.p.) injections of saline (n = 15), Dex 1 µg/kg (n = 15), Dex 10 µg/kg (n = 15), or Dex 100 µg/kg (n = 15) twice (at 1 hour, then again at 12 hours) after surgery. Twelve hours after the final injection (24 hours post-injury), 10 animals in each group were sacrificed for assessment of cell death with Fluoro-Jade B (FJB) staining, as well as axonal injury and synaptic degeneration assessment with immunofluorescent staining. The remaining mice in each group (n = 5) were sacrificed at 1 week after injury to measure cortical tissue lesion volume with cresyl violet staining. For behavior testing, the CCI-injured mice were placed randomly in 2 groups (n = 8 for each group) and received an i.p. injection of saline or Dex at a dose of 100 µg/kg of body weight. Sham surgery mice (n = 8) were used as a control.

Tissue Processing. All animals were deeply anesthetized with Avertin and then perfused transcardially with cold saline, followed by a fixative containing 4% paraformaldehyde (PFA) in PBS. The brains were removed, post-fixed overnight in PFA, and cryoprotected for 48 hours in 30% sucrose. Serial 30 µm thick coronal sections were cut using a cryostat (Leica CM 1950), and stored at −20°C. The sections were then processed for histopathological analysis.

Histological Analysis. Fluoro-Jade B (FJB) staining was used for evaluating neuronal cell death and as immunofluorescent staining for examining the pathological changes. Cresyl violet staining was used for measuring cortical cavity volume as we previously reported4,26–30.

Fluoro-Jade B Staining. Frozen sections were mounted on Superfrost plus slides (Fisher Scientific), were rinsed in distilled water for 2 minutes to rehydrate, and were transferred to a solution of 0.06% potassium permanganate for 20 minutes. The sections were then rinsed in distilled water for 2 minutes and placed in a 0.0004% FJB solution containing 0.1% 4’,6-Diamidino-2-phenylindole (DAPI, Sigma) for 20 minutes. Finally, the stained slides were washed in distilled water, dehydrated thoroughly, and then mounted with DPX (Sigma).

Neuronal Cell Death Counting in the Cortex. The density of FJB-positive cells in the spared cortex surrounding the impact area following TBI was determined through a stereological analysis (10 mice for each group). Three sections per mouse in each group were chosen at 24 hours after TBI based on their close proximity to the epicenter of the impact, and the density of FJB-positive cells was quantified. Though rare, regions of tissue that were already dead and no longer had any positive FJB signals were not included in the measuring. Using Stereo Investigator software (MicroBrightfield Inc., Williston, VT), the tissue boundaries were defined and traced at 5× magnification on an Axio Imager M2 microscope (Zeiss). FJB-positive neuron counting was performed using a systematic sampling site method of the selected tissue area at 40× magnification for accurate recognition. The tissue volume for each site was set at 300 × 300 µm² and the counting frame was 100 × 100 µm². FJB-positive cells were selected based on morphology and fluorescent signal strength. After both the population of FJB-positive cells and the specified tissue volume (in cubic millimeters) were obtained, the density of cells per cubic micrometer was calculated using the following formula: cell density = (cell population)/(tissue volume #/mm³).

Neuronal Cell Death Counting in the Hippocampus. Following the method used in our previous report4, 24 hours after TBI, the total number of FJB-positive cells in the dentate gyrus (DG) of the hippocampus was determined through a blinded quantitative histological analysis (10 mice for each group). Whole sets of 1 in 6 sections covering the entire extent of the hippocampal formation were selected for assessment with FJB staining. Every FJB-positive cell was counted and was determined under a fluorescent microscope with a 20× objective. Finally, the total number of FJB-positive cells on any given section were summed.

Immunofluorescent Staining. Immunofluorescent staining was carried out according to our previous reports27,28. In brief, sections were rinsed in PBS 3 times (5 minutes each) and incubated in blocking buffer (0.1% Triton X-100, 1% bovine serum albumin, and 5% normal serum in PBS) for 1 hour at room temperature. Then, primary antibodies were added to blocking buffer and incubated with sections overnight at 4°C. After 3 washes with PBS (5 minutes each), sections were incubated with the secondary antibody for 1 hour at room temperature and then treated with 4’,6-Diamidino-2-phenylindole (DAPI) for 2 minutes. Finally, sections were washed 3 times with PBS (5 minutes each), dried, and mounted using Fluoromount G (Southern Biotech, Birmingham, AL, USA). Primary antibodies and their final concentrations were as follows: β-APP antibody (1:1000, rabbit, Invitrogen, 36-6900), synaptophysin antibody (1:1000, mouse, Millipore, MAB5258), Iba1 antibody (1:200, goat,
Abcam, ab5076), GFAP antibody (1:1000, mouse, Sigma, G3893), and NG2 antibody (1:200, rabbit, Millipore, AB5320). Secondary antibodies from Jackson ImmunoResearch Laboratories Inc. were all applied at the same dilution of 1:1000.

Cresyl Violet Staining. Briefly, frozen sections were mounted on Superfrost plus slides (Fisher Scientific, Pittsburgh, PA, USA) and stained using 0.1% cresyl violet solution for 20 minutes. Stained sections were rinsed in double-distilled water quickly and were immersed in 95% ethanol for 2 minutes. Then, the sections were dehydrated in 100% ethanol and were cleared in 100% xylene twice (5 minutes each time). Finally, the sections were mounted with DPX for imaging.

Cortical Cavity Volume Measurement. Briefly, whole sets of 1-in-6 series of 30-μm-thick brain sections (7 days after TBI, 180 μm apart) were stained with cresyl violet to show the spare cortex. Then, boundary contours of the contralateral and ipsilateral spare cortex were drawn using AxioVision software (version 4.8, Zeiss, Thornwood, NY, USA). The enclosed volume within the contours was measured, and the percent cortex of the cavity was calculated with the following formula: percentage of the cortical cavity = (contralateral cortex volume − ipsilateral spare cortex volume)/(contralateral cortex volume) × 100%.

Imaging. The images were taken at a primary magnification of 10 ×, 40 ×, and 63 × using an invert microscopy system (Zeiss, Axiovert 200 M) interfaced with a digital camera (Zeiss, Axio Cam MRc5) controlled by a computer.

Rotarod Test. For motor function analysis, the rotarod test was used. Twenty-four mice were tested, with 8 mice in each of 3 groups (Sham, TBI + saline, and TBI + Dex). During the test, each animal was allowed to remain stationary for 10 seconds at 0 rpm. The speed was steadily increased by 3 rpm in 10-second intervals until the maximum of 30 rpm was reached. There were 5 trials each day for each mouse with a 20-minute interval between trials. The first rotarod test was performed before surgery to obtain a baseline. After surgery, the rotarod test was administered 2 times, at 3 days and 7 days after surgery. Duration on the stage was recorded and analyzed.

Statistical Analysis. All data are presented as mean ± standard error of the mean (SEM). The SPSS18.0 program was used for data analysis. For cell death and tissue cavity analyses, statistical significance was determined by one-way ANOVA followed by an LSD test. For behavior tests, statistical significance was first determined by repeated measures, followed by one-way ANOVA and an LSD test to analyze specific time points between the 3 groups.

Statistical significance was determined at the P < 0.05 level.

**Results**

Post-injury Treatment with Dex Significantly Decreased TBI-Induced Cortical Lesion. The high incidence of neurological deficits and mortality after TBI has been attributed in large part to dramatic secondary cell death in the cortex that resulted in massive tissue loss in the cortex. To examine the effects of Dex on tissue incidence of neurological deficits and mortality after TBI has been attributed in large part to dramatic secondary cell death in the cortex that resulted in massive tissue loss in the cortex 31. To examine the effects of Dex on tissue death in the cortex, we found that Dex showed significant protection against hippocampal granular neuron cell death even at the low dose of 1 μg/kg. These data suggested that Dex treatment protected the hippocampus from injury at a much lower dose than in the cortex.

Dex Treatment Prevents Neuronal Cell Death in the Hippocampal Dentate Gyrus after Moderate TBI. TBI not only causes cell death in the cortex, but also induces significant cell death in the hippocampus. To quantify cell death in the hippocampus, FJB staining was performed. The results showed that the FJB-positive cells in the hippocampus decreased as the dose of TBI increased. The number of FJB-positive cells in the DG of hippocampus was 1701.1 ± 235.5 (saline group, Fig. 3A), 1214.8 ± 193.0 (1 μg/kg Dex group, Fig. 3B), 1047.0 ± 140.2 (10 μg/kg Dex group, Fig. 3C), and 917.2 ± 119.6 (100 μg/kg Dex group, Fig. 3D), respectively. Unlike what we observed in the cortex, we found that Dex treatment showed significant protection against hippocampal granular neuron cell death at the low dose of 1 μg/kg. These data suggested that Dex treatment protected the hippocampus from injury at a much lower dose than in the cortex.
Dex Treatment Prevents Axonal Damage in the Cortex after Moderate TBI. Axonal injury is often observed following TBI. Therefore, we assessed the potential of Dex to protect against secondary axonal damage. The results above indicated that Dex at the dose of 100 µg/kg not only decreased cortical lesion, but also prevented neuronal cell death in the cortex and in the hippocampus induced by moderate TBI. Thus, we determined whether Dex at this dose could protect axons from injury. After receiving moderate TBI, the mice had two 100 µg/kg Dex treatments at 1 and 12 hours after injury. The mice were then sacrificed at 24 hours after injury for assessing axonal injury with β-APP staining, which is a sensitive method to detect early axonal injury. In the sham group, no β-APP immunoreactivity was observed in the cortex (Fig. 4A), including the corpus callosum (Fig. 4B), peri-injury region (Fig. 4C), and remote region (400 µm away from epicenter) (Fig. 4D). Twenty-four hours after moderate TBI, strong immunoreactive β-APP-positive axonal profiles appeared in the cortex (Fig. 4E) indicating dramatic axonal damage after moderate TBI. The corpus callosum area revealed β-APP immunoreactivity in the form of thick and short filaments (Fig. 4F) and the peri-injury (Fig. 4G) and remote regions (Fig. 4H) of the cortex revealed β-APP immunoreactivity in the form of small globules and granules (Fig. 4G). Treatment with Dex significantly reduced β-APP staining (Fig. 4I-L). As shown in Fig. 4I, the Dex treatment group exhibited weaker β-APP immunoreactivity in the cortex after moderate TBI. The immunoreactivity was in the form of fewer and smaller globules and granules in the corpus callosum (Fig. 4I) and the peri-injury region (Fig. 4K), while the remote region was almost negative for β-APP staining (Fig. 4L). We did not detect positive β-APP signals in...
the contralateral hemisphere of TBI brain either with saline or Dex treatment 24 hours after TBI (Suppl. Figure 1a–c). These results demonstrated that 100 µg/kg Dex treatment could prevent axonal damage in the cortex after moderate TBI.

**Dex Treatment Prevents Synaptic Degeneration in the Injury Area.** To further determine whether Dex has the preventive effects on synaptic degeneration, immunostaining with an anti-synaptophysin antibody was performed to detect presynaptic boutons. Three regions in the cortex were chosen for evaluating synaptophysin staining according to the distance from the edge of the cortex cavity (200, 400, and 800 µm) (Fig. 5A,E, and I). In the sham control animals, synaptophysin immunostaining was observed in a punctate distribution, consistent with localization of presynaptic boutons (Fig. 5B–D). Cell nuclei showed negligible synaptophysin immunoreactivity (Fig. 5B–D). In the TBI-injured brains (Fig. 5E–H), the intensities of synaptophysin staining and numbers of synaptophysin-positive puncta were reduced at the corresponding anatomic positions in the cortex. (n = 10, *p < 0.05).

![Figure 2](image-url)  
**Figure 2.** TBI-induced neuronal cell death in the cortex is decreased by intraperitoneal injection of 100 µg/kg Dex. Fluoro-Jade B (FJB) staining was performed to assess the neuronal cell death in the cortex that received saline or different concentrations of dexmedetomidine (Dex) treatment following moderate traumatic brain injury (TBI). (A) Schematic diagram of neuronal cell death counting. The regions enclosed by white lines were counting regions and the region enclosed by a red line was the region where higher magnification images were taken. (B) Neuronal cell death of saline treatment mice after TBI. (C) Neuronal cell death of 1 µg/kg Dex treatment mice after TBI. (D) Neuronal cell death of 10 µg/kg Dex treatment mice after TBI. (E) Neuronal cell death of 100 µg/kg Dex treatment mice after TBI. (F) Quantitative measurement of the neuronal cell death in the cortex. (n = 10, *p < 0.05).
cortex, indicating that moderate TBI results in synaptic degeneration in the injury area. Dex treatment partially rescued synaptic degeneration indicated by increasing intensity of synaptophysin staining (Fig. 5I–L). When we further assessed the intensity and density of synaptophysin-positive signals in the contralateral side of the cortex, we found no detectable changes after TBI or after Dex treatments (Suppl. Figure 1d–f). The results indicated that Dex treatment prevented synaptic degeneration in the injury area.

Dex Treatment Improved Behavior Outcomes. The above data showed that Dex treatment reduced the cortex cavity, prevented cell death both in cortex and hippocampus, and mitigated axonal and synaptic degeneration. These neuroprotective effects on cellular and tissue levels may contribute to neurobehavioral improvement. Therefore, we then further evaluated motor function using the rotarod test.

Before surgery, we assessed the motor performance of the mice on the rotarod test to determine a baseline. Their duration on the stage was recorded and analyzed. Data showed that their durations on the stage were similar between different groups before surgery (Sham 32.27 ± 4.77 seconds; TBI + saline 31.74 ± 2.08 seconds; and TBI + Dex 33.83 ± 2.23 seconds). After surgery, the rotarod test was given 2 times at 3 days and 7 days, respectively (Fig. 6A). On the third day after surgery, the duration of the Sham group was increased compared to baseline (from 32.27 ± 10.66 seconds to 47.23 ± 3.77 seconds); this increased duration may have been due to the mice acquiring skill. Meanwhile, the duration of the TBI group with saline treatment showed a dramatic decrease

---

**Figure 3.** TBI-induced neuronal cell death in the hippocampus is reduced by intraperitoneal injection of 100 µg/kg Dex. Fluoro-Jade B (FJB) staining was performed to assess the neuronal cell death in the hippocampus that received saline or different concentrations of dexmedetomidine (Dex) treatment following traumatic brain injury (TBI). (A) Neuronal cell death of saline treatment mice after TBI. (B) Neuronal cell death of 1 µg/kg Dex treatment mice after TBI. (C) Neuronal cell death of 10 µg/kg Dex treatment mice after TBI. (D) Neuronal cell death of 100 µg/kg Dex treatment mice after TBI. (E) Quantitative measurement of the neuronal cell death in the hippocampus. (n = 10, *p < 0.05).
from $31.74 \pm 2.08$ seconds to $21.78 \pm 1.71$ seconds, $p < 0.001$). Dex treatment resulted in some degree of attenuation of duration dropping after TBI at this time point compared to the saline group, but did not reach statistical significance ($26.91 \pm 1.52$ seconds compared to saline treatment $21.78 \pm 1.71$ seconds, $p > 0.05$). Seven days after TBI, duration in all groups increased, because of spontaneous recovery. The Dex treatment exhibited a much faster recovery rate than saline control. The duration of the Dex treatment group increased to $42.6 \pm 3.09$ seconds at this time point, which was significantly higher than the saline treatment group ($28.29 \pm 2.77$, $p < 0.01$, Fig. 6B). This result demonstrated that Dex treatment improved the motor function recovery following moderate TBI.

Discussion

TBI is the major cause of death in young adults and often leads to substantial cognitive impairment, motor dysfunction, and epilepsy. Besides the severity of primary damage, secondary damage is an important determinant of a patient’s outcome. The secondary damage includes an entire cascade of cellular, chemical, tissue, and blood vessel changes in the brain that contribute to further destruction of brain tissue. Numerous studies have expanded our knowledge of TBI’s pathophysiological events and could potentially serve as the basis to refine established strategies or even define new treatments. However, there is no effective treatment for the disorders caused by TBI. Currently, pharmacologic sedation is the first-line treatment for severe TBI to control intracranial pressure. An ideal agent for sedation in the TBI patient population would be fast-acting with a short elimination half-time, allow for serial clinical examinations, accomplish adequate sedation in a dose-dependent fashion, be neuroprotective, have anti-epileptic properties and analgesic properties, and have no adverse effects on major organ systems. However, common agents include propofol and benzodiazepines, which interfere with serial neurologic evaluations, cause significant respiratory depression and hypotension, and may prolong time spent intubated in Intensive Care Units (ICU).

Unlike propofol and the benzodiazepines, which act through the GABA\textsubscript{A} receptor, dexmedetomidine (Dex) is an alpha-2 receptor adrenergic agonist with high selectivity about 7 to 8 times that of clonidine. Moreover, it is an FDA approved drug with a relatively short elimination half-time of almost 2 hours that is currently used in the sedation of humans. Furthermore, Dex is found to be safe and efficacious, and has no side effects on respiratory rate or oxygen saturations. This enables it to be continued after extubation. However, there have been relatively few studies examining the role of Dex in patients with TBI. Aryan et al. reported its use in 39 neurosurgical patients in the ICU and concluded that Dex can be a safe and effective sedative agent for neurosurgical patients. Grof et al. undertook a small, prospective, observational study of patients receiving Dex in a neurosurgical ICU. Overall, the role of Dex in patients with TBI has yet to be adequately explored and more investigation is merited.
One *in vitro* TBI model study showed the neuroprotective effect of Dex in hippocampal slice cultures undergoing direct impact. Thus, our study was aimed at demonstrating histological evidence of neuroprotection while using Dex *in vivo*. This investigation could potentially pave the way to clinical trials investigating Dex as an...
adjunct sedation in the TBI population. High-resolution images and quantified data showed that post-injury treatment with 100 µg/kg Dex reduced cortical tissue cavity volume in the TBI group. Further experiments proved that injecting a dose of 100 µg/kg Dex could also reduce neuronal cell death in the cortex and hippocampus in the TBI group. To further investigate more favorable effects of Dex at the dose of 100 µg/kg on moderate TBI, we focused on axonal damage, which is one of the most common and important pathologic features of TBI46. Our results indicated that 100 µg/kg Dex could prevent axonal damage dramatically in the cortex after moderate TBI. Our previous studies have shown moderate TBI causes acute synaptic degeneration in both the hippocampal dentate gyrus41 and cerebral cortex42. The findings have led us to wonder if Dex has preventive effects on synaptic degeneration. We found that Dex at the dose of 100 µg/kg did rescue synaptic degeneration in the cortex and improved functional recovery after moderate TBI. Taken together, Dex at 100 µg/kg dosing had a significant neuroprotective effect for this in vivo model.

A few study limitations are noted; the mechanism of how Dex exerts a neuroprotective effect on TBI remains unknown. Recent evidence suggests that this effect is mediated not only by the alpha-2 agonistic properties of Dex, but also by its binding to imidazoline I1-receptors43. In addition, obvious hypothermia was found in the mice that received a 100 µg/kg Dex injection. Thus, we speculate that the neuroprotective effects of Dex on TBI may not only be due to the activation of a signal transduction cascade linked to alpha-2 adrenergic receptors, but also due to the hypothermia induced by Dex. The mechanism of action of the demonstrated neuroprotective effect thus requires further investigation.

Conclusion
Taken together, in an in vivo murine model of TBI, Dex at the dose of 100 µg/kg not only prevented tissue loss and cell death, but also reduced axonal injury and synaptic degeneration caused by TBI, resulting in improvement of motor function.

References
1. Faul, M., Xu, L., Wald, M. M. & Coronado, V. G. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, (2010).
2. Langlois, J. A., Rutland-Brown, W. & Wald, M. M. The epidemiology and impact of traumatic brain injury: a brief overview. J Head Trauma Rehabil 21, 375–378 (2006).
3. Salmon, C. H. & Sahakian, B. J. Cognitive outcome in traumatic brain injury survivors. Curr Opin Crit Care 11, 111–116 (2005).
4. Sivanandam, T. M. & Thakur, M. K. Traumatic brain injury: a risk factor for Alzheimer's disease. Neuroscience and biobehavioral reviews 36, 1376–1381 (2012).
5. Marras, C. et al. Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Archives of physical medicine and rehabilitation 95, S238–244 (2014).
6. Hendricks, H. T., Geurts, A. C., van Ginneken, B. C., Heeren, A. J. & Vos, P. E. Brain injury severity and autonomic dysregulation accurately predict heterotopic ossification in patients with traumatic brain injury. Clin Rehabil 21, 545–553 (2007).
7. Steifel, M. E., Tomita, Y. & Marmarou, A. Secondary ischemia impairing the restoration of ion homeostasis following traumatic brain injury. J Neurosurg 103, 707–714 (2005).
8. Yi, J. H. & Hazell, A. S. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int 48, 394–403 (2006).
9. Alzheimer, C. & Werner, S. Fibroblast growth factors and neuroprotection. Adv Exp Med Biol 513, 335–351 (2002).
10. Xiong, Y. et al. Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J Neurosurg 109, 510–521 (2008).
11. Xiong, Y. et al. Role of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in mice. Brain Res 1185, 301–312 (2007).
12. Xiong, Y. et al. Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose. J Neurotrauma 113, 598–608 (2009).
13. Wu, C. H. et al. Post-Injury Treatment with 7,8-Dihydroxyflavone, a TrkB Receptor Agonist, Protects against Experimental Traumatic Brain Injury via P38/ Akt Signaling. PLoS One 9, e113397 (2014).
14. Chen, L., Gao, X., Zhao, S., Hu, W. & Chen, J. The Small-Molecule TrkB Agonist 7, 8-Dihydroxyflavone Decreases Hippocampal Newborn Neuron Death After Traumatic Brain Injury. J Neuropathol Exp Neurol 74, 557–567 (2015).
15. Seating, G. M. Dexametomidine: A Review of Its Use for Sedation in the Intensive Care Setting. Drugs 75, 1119–1130 (2015).
16. James, M. L., Olson, D. M. & Graffagnino, C. A pilot study of cerebral and haemodynamic physiological changes during sedation with dexametomidine or propofol in patients with acute brain injury. Anaeth Intensive Care 40, 949–957 (2012).
17. Wang, X., Li, J., Fen, L. & Wang, A. Effects of dexametomidine on cerebral blood flow in critically ill patients with or without traumatic brain injury: a prospective controlled trial. Brain Inj 27, 1617–1622 (2013).
18. Cai, Y., Xu, H., Yan, J., Zhang, L. & Lu, Y. Molecular targets and mechanism of action of dexametomidine in treatment of ischemia/ reperfusion injury. Mol Med Rep 9, 1542–1550 (2014).
19. Laudenbach, V. et al. Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexametomidine. Anesthesiology 96, 134–141 (2002).
20. Chen, X. R., Besson, V. C., Bezaud, T., Plotkine, M. & Marchand-Leroux, C. Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury. J Pharmacol Exp Ther 326, 966–974 (2008).
21. Schroeppel, T. J. et al. Beta-adrenergic blockade and traumatic brain injury: protective? J Trauma 69, 776–782 (2010).
22. Bansal, V. et al. Vagal Stimulation Modulates Inflammation through a Ghrelin Mediated Mechanism in Traumatic Brain Injury. Inflammation 35, 214–220 (2012).
23. Schoeler, M. et al. Dexametomidine is neuroprotective in an in vitro model for traumatic brain injury. BMC Neurology 12, 20 (2012).
24. Gao, X. et al. Selective death of newborn neurons in hippocampal dentate gyrus following moderate experimental traumatic brain injury. Journal of neuroscience research 86, 2258–2270 (2008).
25. Gao, X., Enikolopov, G. & Chen, J. Moderate traumatic brain injury promotes proliferation of quiescent neural progenitors in the adult hippocampus. Experimental neurology 219, 516–523 (2009).
26. Gao, X. & Chen, J. Moderate traumatic brain injury promotes neural precursor proliferation without increasing neurogenesis in the adult hippocampus. Experimental neurology 239, 38–48 (2012).
27. Gao, X., Wang, X., Xiong, W. & Chen, J. In vivo reprogramming reactive glia into iPSCs to produce new neurons in the cortex following traumatic brain injury. Sci Rep 6, 22490 (2016).
28. Ibrahim, S. et al. Traumatic Brain Injury Causes Aberrant Migration of Adult-Born Neurons in the Hippocampus. *Sci Rep* 6, 21793 (2016).
29. Wang, X., Gao, X., Michalski, S., Zhao, S. & Chen, J. Traumatic Brain Injury Severity Affects Neurogenesis in Adult Mouse Hippocampus. *Journal of neurotrauma* 33, 721–733 (2016).
30. Zhao, S., Gao, X., Dong, W. & Chen, J. The Role of 7,8-Dihydroxyflavone in Preventing Dendrite Degeneration in Cortex After Moderate Traumatic Brain Injury. *Mol Neurobiol* 53, 1884–1895 (2016).
31. Stoica, B. A. & Faden, A. I. Cell death mechanisms and modulation in traumatic brain injury. *Neurotherapeutics* 7, 3–12 (2010).
32. Johnson, V. E., Stewart, W. & Smith, D. H. Axonal pathology in traumatic brain injury. *Experimental neurology* 246, 35–43 (2013).
33. Gentleman, D. Causes and Effects of Systemic Complications among Severely Head Injured Patients Transferred to a Neurosurgical Unit. *Int Surg* 77, 297–302 (1992).
34. Flower, O. & Hellings, S. Sedation in traumatic brain injury. *Emerg Med Int* 2012, 637171 (2012).
35. Miao, Y., Zhang, Y., Wan, H., Chen, L. & Wang, F. GABA-receptor agonist, propofol inhibits invasion of colon carcinoma cells. *Biomed Pharmacother* 64, 583–588 (2010).
36. Grof, T. M. & Bledsoe, K. A. Evaluating the Use of Dexmedetomidine in Neurocritical Care Patients. *Neurocritical Care* 12, 356–361 (2010).
37. Dahmani, S. et al. Dexmedetomidine increases hippocampal phosphorylated extracellular signal-regulated protein kinase 1 and 2 content by an alpha 2-adrenoceptor-independent mechanism: evidence for the involvement of imidazoline I1 receptors. *Anesthesiology* 108, 457–466 (2008).

Acknowledgements
This study was supported by the Goodman Campbell Foundation and the Natural Science Foundation of China (No. 81402217).

Author Contributions
J.W.: collection and assembly of data, data analysis and interpretation, manuscript writing. T.V.: collection and assembly of data, data analysis and interpretation; X.G.: collection and assembly of data, data analysis and interpretation; B.L.: Data analysis; C.K.: Data analysis and manuscript revision; J.C.: conception and design, assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-23003-3.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018